AAIC 2026 findings show a blood test raised primary-care accuracy from 65% to 93% for mild cognitive impairment or dementia. Mild cognitive impairment means early memory slips that spare daily tasks, and specific visit questions can clarify test use. The Alzheimer's Association reports this result in the AAIC primary-care results.
The test is PrecivityAD2 for adults 40 and older with cognitive symptoms. It is an aid alongside history, exam, and cognitive testing, not a standalone diagnosis. The Alzheimer's Association describes this use in the FDA clearance announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the primary-care study test?
- Could this test apply to you?
- What questions should you bring to the visit?
- What limits should you know first?
What did the primary-care study test?
Lund University researchers enrolled 1,310 Swedish patients with mild cognitive impairment or dementia. A total of 165 primary-care and specialty physicians assessed them before and after seeing blood results. PrecivityAD2 measures amyloid-beta 42/40 plus phosphorylated tau 217, a marker linked to Alzheimer's pathology.
AJMC notes it uses two cutoffs to return positive or negative classifications validated against spinal fluid and PET. In that Alzheimer's Association release, primary-care accuracy rose from 65% to 93% after physicians saw results. That release puts specialists near 90%, so blood results brought primary care to specialist level.
Could this test apply to you?
According to the Alzheimer's Association, the FDA cleared PrecivityAD2 in August 2026 for adults 40 and older with cognitive symptoms. It is an aid to history, exam, cognitive testing, and clinician judgment, not a standalone diagnosis.
Bring the visit if you notice lasting memory slips, word-finding trouble, or getting lost in familiar tasks. Bring a family member who sees daily changes and a list of drugs, sleep issues, and mood changes.
- age 40 or older with ongoing cognitive symptoms
- mild cognitive impairment or dementia under evaluation
- willing to pair blood results with exam and cognitive testing
What questions should you bring to the visit?
After seeing blood results, physicians changed diagnoses in about one-third of patients. They changed planned management, follow-up exams, or referrals in more than half, including 55.9% in primary care. The Alzheimer's Association AAIC release reports both shifts.
Use those numbers to ask what a result would change for you. Take notes and ask for plain-language answers you can review later. Ask which follow-up is scheduled and who will explain new symptoms. Ask when to return sooner and what care planning starts now.
- Am I a candidate for PrecivityAD2 given my symptoms and age?
- What will a positive, negative, or borderline result change in my diagnosis?
- Will results change drugs, follow-up tests, referrals, or safety planning?
- Do I need PET or spinal-fluid confirmation after this blood test?
- How should family use risk estimates for planning next 5 to 10 years?
What limits should you know first?
Not every blood test can replace PET or spinal-fluid testing. The 2025 Alzheimer's Association guideline sets strict accuracy cutoffs. Patient Care Online notes only 90%/90% tests may substitute, while 90%/75% tests may only rule out disease in the guideline summary. A pooled analysis of nearly 2,700 cognitively unimpaired adults averaging age 70 tracked plasma p-tau217.
The Alzheimer's Association reports very high levels over twice the average predicted about 38% risk at 5 years and 78% at 10 years. Patient Care Online notes slightly elevated levels just above average still carried 15% risk at 5 years and 45% at 10 years. Use this graded risk to discuss timelines, safety steps, and support, not to assume a fixed future. Ask your clinician what your exact level, cutoff, and follow-up plan mean for you next.
You Might Also Like
- The NIA 2026 Dementia Care and Caregiving Summit Report: Questions Adult Children Can Ask Local Care Programs
- The $781 Billion Dementia Economic Estimate in the 2026 NIA Report: Questions Adult Children Can Ask Local Care Programs
- Caregiver Job and Retirement Losses in the 2026 NIA Report: Questions Adult Children Can Ask Local Care Programs
